home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Rethinking Tumour Spread

  April, 3 2009 3:07
your information resource in human molecular genetics
Accumulating clinical and genetic data indicate that cancer metastasis might occur much earlier in the course of disease than previously thought, even before the primary tumour is clinically detectable. Considering these data in a Perspective article in Nature Reviews Cancer, Christoph Klein proposes a sea change in how we view metastatic spread, which has important implications for the treatment of patients with cancer.

The long-held model of metastasis states that tumour cells leave to form metastatic tumours when the primary tumour has grown large. This allows time for the tumour cells to evolve characteristics that enable them to invade and grow elsewhere in the body. Klein presents the controversial 'parallel progression model' which proposes that tumour cells spread to distant sites when the primary tumour is still small. After they have migrated, they then develop the traits required to survive and grow within the tissues that they have invaded.

Doctors inform their decisions based on the size and molecular traits of primary tumours and the presence of detectable metastases, so this model could incite a re-evaluation of how cancer is diagnosed and treated.

This article is one of seven articles addressing key questions in the biology of metastasis that comprise a Focus on Migration and metastasis in the April 2009 issue of Nature Reviews Cancer (freely available online for 3 months at FOCUS on MIGRATION and METASTASIS).

Author contact:

Christoph Klein (University of Regensburg, Germany)
E-mail: christoph.klein@klinik.uni-regensburg.de

(C) Nature Reviews Cancer press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.